Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company’s web site at www.cyclacel.com.
- 17 years ago
QualityStocks
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Gloo Holdings, Inc. (NASDAQ: GLOO) Prices $72.8 Million IPO
Gloo (NASDAQ: GLOO) , a technology platform serving the faith and flourishing ecosystem, priced its…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Positioned for Growth as War Department Launches Billion-Dollar Push for U.S. Drone Dominance
Safe Pro Group (NASDAQ: SPAI), a mission-driven provider of AI-powered defense and security solutions, is…
-
QualityStocksNewsBreaks – Decent Holding Inc. (NASDAQ: DXST) Closes $8 Million Registered Offering of Class A Shares and Warrants
Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8…